Sign up
Pharma Capital

VolitionRx appoints new finance head

Cameron Reynolds, Volition’s chief executive, expressed confidence that Vanston would add value as VolitionRx becomes a revenue-generating company.
picture of handshake
Vanston has experience across a range of sectors

Cancer diagnostics group VolitionRx Limited (NYSE MKT:VNRX) has appointed David Vanston as its new chief financial officer with immediate effect. 

Vanston joins from Octo Telematics, a technology company based in Boston, where he was the Senior Controller for its US business.

Before this, he spent 20 years with globally-listed companies in a variety of sectors spanning manufacturing and technology to life sciences .

Cameron Reynolds, Volition’s chief executive, expressed confidence that Vanston would add value as VolitionRx becomes a revenue-generating company.

Former CFO David Kratochvil tendered his resignation in November, but stayed on until a successor was found.

 

PhilW.jpg
Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile

VolitionRx Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.